In the News

Basal-bolus insulin may require fewer increases in daily doses than other insulin regimens

An observational trial compared insulin glargine once daily, biphasic insulin twice daily, and biphasic insulin three times daily with a basal-bolus regimen of rapid-acting insulin analogue three times daily and long-acting insulin once daily.

Oral glucose tolerance test results may be influenced by height, study finds

Among both men and women in Finland, height was inversely associated with two-hour plasma glucose concentration, except among patients with a body-mass index of 35 kg/m2 or more.

SGLT2 inhibitors may have class effect for reduction of cardiac risk

The industry-funded study used international data to compare rates of heart failure hospitalization and mortality in patients on sodium glucose cotransporter-2 (SGLT2) inhibitors or other glucose-lowering drugs.

MKSAP quiz: Closed-loop insulin systems

This month's quiz asks readers to consider a closed-loop insulin-delivery system (artificial beta cell) for a 25-year-old woman with type 1 diabetes and frequent hypoglycemia.

Spotlight on the Diabetes Prevention Program

Data from the Diabetes Prevention Program (DPP) Outcomes Study showed little effect of diabetes prevention efforts on patients' cognition or coronary artery calcium, according two recent studies.

Bariatric surgery improved HbA1c at 5 y more than intensive medical care alone in obese patients with T2DM

A commentary considers the industry-funded STAMPEDE trial, in which obese patients with type 2 diabetes were randomly assigned to intensive medical therapy alone or intensive medical therapy plus Roux-en-Y gastric bypass or sleeve gastrectomy.

Canagliflozin will receive new boxed warning about amputation risks

Canagliflozin (Invokana, Invokamet) increases patients' risk of leg and foot amputations, according to new data from two clinical trials, the FDA recently announced.